Sobhani I, Chastang C, De Korwin J D, Lamouliatte H, Mégraud F, Guerre J, Elouaer-Blanc L
Service de Gastroentérologie, Hôpital Bichat, Paris.
Gastroenterol Clin Biol. 1995 Mar;19(3):252-8.
Reduction of gastric acid secretion by maintenance therapy and eradication of Helicobacter pylori by antibiotic treatment have been shown to reduce duodenal ulcer relapse. This study compared the effect of two regimens, a 6-month maintenance on an H2 receptor antagonist versus a one-week antibiotic therapy, on the rate of duodenal ulcer relapse in duodenal ulcer patients with gastric H. pylori infection.
We conducted a 30-week, double-blind, double-dummy, multicentric clinical trial involving 119 patients (97 M, 22 F, mean age 39 +/- 14 years) randomly assigned to a daily dose of 40 mg famotidine for 6 weeks supplemented with, during the first week, either antibiotics (500 mg amoxicillin q.i.d. and 500 mg tinidazole t.i.d.-antibiotic group) or their placebo (maintenance group). Healed patients after 6 weeks entered the 6-month maintenance phase: the maintenance group received 20 mg famotidine at bedtime and the antibiotic group, a placebo. Endoscopy with antral biopsies was performed to allow a rapid urease test, culture and histological examination upon entry, after 6 weeks, 3 months, and 6 months and, whenever symptoms recurred. H. pylori status was regarded as positive if any one of these three tests was positive, and negative if all tests were negative.
The 2 treatment groups were well balanced for all baseline characteristics. After 6 weeks, H. pylori was eradicated in 25 (45%) patients in the antibiotic group, and in 1 (2%) in the maintenance group (P < 0.01). In term of intention-to-treat, there was no significant difference in the healing rate after 6 weeks (93 and 83% in the antibiotic and maintenance groups, respectively; P = 0.15) or in the relapse rate after 6 months (13 and 28% in the antibiotic and maintenance groups, respectively; P = 0.17 Log-rank test). However, the overall failure rate (absence of healing, relapse) was lower (P = 0.04, Log-rank test) in the antibiotic group in which all relapses but one were observed in H. pylori positive patients. The rate of ulcer relapse (1/20) in patients of antibiotic group who remained free of H. pylori during the study, was significantly (P < 0.01) lower compared with that of H. pylori positive patients in the maintenance group (11/44). During the first 6-week period, more side effects were observed in the antibiotic group than in the maintenance group (4 vs 1 patient, respectively).
Our results indicate no significant difference between ulcer relapse rates after 6 months following a one-week antibiotic therapy or long-term maintenance therapy. Short-term antibiotic therapy should be considered as a valuable alternative to the long-term maintenance therapy.
维持治疗降低胃酸分泌以及抗生素治疗根除幽门螺杆菌已被证明可降低十二指肠溃疡复发率。本研究比较了两种治疗方案,即使用H2受体拮抗剂进行6个月维持治疗与为期1周的抗生素治疗,对合并胃幽门螺杆菌感染的十二指肠溃疡患者十二指肠溃疡复发率的影响。
我们进行了一项为期30周的双盲、双模拟、多中心临床试验,纳入119例患者(97例男性,22例女性,平均年龄39±14岁),随机分为每日服用40mg法莫替丁6周组,在第一周补充抗生素(500mg阿莫西林每日4次和500mg替硝唑每日3次——抗生素组)或其安慰剂(维持组)。6周后愈合的患者进入6个月维持阶段:维持组在睡前服用20mg法莫替丁,抗生素组服用安慰剂。在入组时、6周后、3个月和6个月以及症状复发时,进行内镜检查及取胃窦活检,以便进行快速尿素酶试验、培养和组织学检查。如果这三项检查中的任何一项呈阳性,则幽门螺杆菌状态被视为阳性;如果所有检查均为阴性,则视为阴性。
两个治疗组在所有基线特征方面平衡良好。6周后,抗生素组25例(45%)患者的幽门螺杆菌被根除,维持组1例(2%)患者的幽门螺杆菌被根除(P<0.01)。在意向性分析中,6周后的愈合率(抗生素组和维持组分别为93%和83%;P = 0.15)或6个月后的复发率(抗生素组和维持组分别为13%和28%;P = 0.17,对数秩检验)无显著差异。然而,抗生素组的总体失败率(未愈合、复发)较低(P = 0.04,对数秩检验),其中除1例复发外,所有复发均见于幽门螺杆菌阳性患者。在研究期间幽门螺杆菌仍为阴性的抗生素组患者的溃疡复发率(1/20),与维持组幽门螺杆菌阳性患者的复发率(11/44)相比,显著更低(P<0.01)。在最初的6周期间,抗生素组观察到的副作用比维持组更多(分别为4例和1例患者)。
我们的结果表明,为期1周的抗生素治疗或长期维持治疗6个月后,溃疡复发率无显著差异。短期抗生素治疗应被视为长期维持治疗的一种有价值的替代方案。